Cooke Acquires Mowi's East Canadian Salmon Farms
Money

Cooke Acquires Mowi's East Canadian Salmon Farms

authorBy Mr. Money Mustache
DateJun 30, 2026
Read Time3 min

Seafood giant Cooke has announced a definitive agreement to take over the salmon farming division of its Norwegian competitor, Mowi, located in eastern Canada. This significant transaction, valued at C$225 million (approximately $158.1 million USD), was disclosed by Mowi on June 30th. For Mowi, a publicly traded entity, this divestiture represents a strategic pivot, allowing the company to intensely concentrate its resources and operations on its primary aquaculture territories.

Cooke's acquisition encompasses a comprehensive suite of assets, including state-of-the-art freshwater hatchery facilities, extensive sea farming sites, and two modern processing plants strategically positioned across the Canadian provinces of New Brunswick, Prince Edward Island, and Newfoundland and Labrador. Glenn Cooke, the Chief Executive Officer of Cooke, highlighted the transaction as a pivotal "growth opportunity" for the company's expanding presence in the Atlantic Canada region. He expressed enthusiasm about integrating Mowi Canada East's 250 employees into the Cooke family, emphasizing a collaborative vision to bolster the sector and advance sustainable Atlantic salmon cultivation for both local and international markets. Cooke's immediate objectives following the acquisition involve stabilizing operations and reinvesting through synergistic opportunities with its existing Atlantic Canada farming infrastructure.

The successful completion of this deal is contingent upon thorough due diligence and the fulfillment of standard closing conditions, including necessary regulatory approvals, with an anticipated finalization in the second half of the current year. In anticipation of the sale, Mowi has adjusted its 2026 volume guidance downwards from 605,000 GWT to 600,000 GWT and projects a C$140 million write-down related to the transaction. This acquisition follows Cooke's earlier move in March to secure the debt facilities of Avramar Greece, ultimately gaining operational control of the Greek enterprise. Meanwhile, Mowi has also been active in strategic acquisitions, increasing its stake in Norway's Nova Sea to 95% last October and later agreeing to acquire Torghatten Aqua's seawater salmon farming business in northern Norway, while returning its minority stake to allow Torghatten Aqua to pursue independent land-based operations. Mowi, as detailed in its 2025 annual report, maintains its position as the world's leading Atlantic salmon farmer, contributing significantly to global salmon production.

The dynamic landscape of the seafood industry showcases strategic maneuvers by key players like Cooke and Mowi, reflecting a commitment to optimizing operations and fostering sustainable growth. Such strategic acquisitions not only reshape market dynamics but also underscore a forward-thinking approach towards consolidating resources, enhancing efficiency, and ensuring the long-term viability of sustainable aquaculture practices. These efforts are crucial for meeting global demand for seafood while upholding environmental stewardship and economic prosperity in the communities they serve.

More Articles
Money
German Beverage Industry Opposes Proposed Sugar Tax
Over 300 German beverage companies and industry associations have collectively voiced strong opposition to the government's proposed sugar tax, slated for implementation in 2028. They argue the tax, intended to curb rising healthcare costs, lacks scientific justification, would disproportionately burden consumers and businesses during challenging economic times, and could destabilize the market without effectively addressing public health concerns.
By Natalie PaceJun 30, 2026
Money
Akebia Therapeutics Reinforces Vafseo Patent Portfolio
Akebia Therapeutics has significantly bolstered the intellectual property protection for its key therapeutic, Vafseo (vadadustat), extending its patent coverage through 2036. This strategic move, driven by a new FDA Orange Book listing and a five-year extension for a core patent, enhances the long-term commercial viability of the kidney disease treatment. The company also reported strong Q1 2026 financial results, with Vafseo product revenue reaching $15.8 million and a substantial increase in patient usage and prescribers.
By Natalie PaceJun 30, 2026
Money
Syndax Pharmaceuticals: A Biotech Opportunity Amidst Evolving AML Market Dynamics
Syndax Pharmaceuticals (SNDX) continues to be a promising biotech investment, despite a recent reduction in its price target by Guggenheim due to revised Acute Myeloid Leukemia (AML) market estimates. The company recently published positive Phase 1/2 SAVE trial results for its oral combination regimen (Revuforj, decitabine/cedazuridine, and venetoclax) in relapsed or refractory AML patients, demonstrating an 88% overall response rate. This underscores Syndax's potential in hematologic malignancies.
By Scott PapeJun 30, 2026
Money
MapLight Therapeutics: A Biotech Stock to Watch
MapLight Therapeutics (MPLT) is gaining attention as a promising biotech company, particularly with its advancements in treating schizophrenia and Alzheimer's disease. Raymond James initiated coverage with a "Strong Buy" rating, anticipating positive results from the upcoming ZEPHYR trial for ML-007C-MA. The company also reported clinically meaningful improvements in irritability for adolescents with autism spectrum disorder in its Phase 2 IRIS trial. MPLT focuses on central nervous system disorders using innovative neurotechnologies.
By JL CollinsJun 30, 2026
Money
Takeda's Pharmaceutical Innovations: Growth Prospects Amidst Promising Clinical Trial Results and Regulatory Milestones
Takeda Pharmaceutical Company Limited is demonstrating significant growth potential through its recent advancements in biopharmaceutical research and development. The company announced positive Phase 3 results for zasocitinib in plaque psoriasis, showcasing superior efficacy and a favorable safety profile. Additionally, the U.S. FDA accepted its application for ENTYVIO IV, aiming to expand treatment options for pediatric inflammatory bowel diseases. These milestones position Takeda for enhanced market presence and address crucial unmet medical needs.
By Natalie PaceJun 30, 2026